HerAnova reports strong validation data for endometriosis blood test

HerAnova presented clinical validation data for HerResolve, its blood-based endometriosis test, at the 2026 Endocrine Society Annual Meeting in Chicago. The study found high diagnostic performance and suggested the assay can identify cases missed by ultrasound or MRI, a potential step toward earlier diagnosis for symptomatic women. Why it matters: - Endometriosis affects about 1 in 10 women of reproductive age, but diagnosis often takes seven to 10 years. - HerResolve is designed as a non-invasive triage tool that could reduce reliance on laparoscopic surgery for diagnosis. - Earlier detection can shorten delays to treatment and may help preserve fertility and reduce pain. What happened: - HerAnova Lifesciences presented clinical validation data on HerResolve at the 2026 Endocrine Society Annual Meeting, held June 13-16 in Chicago. - The poster was titled “Non-Invasive Blood-Based Detection of Endometriosis Has Potential to Improve Standard of Care Among Symptomatic Women.” - The research evaluated HerResolve against laparoscopic visualization and histopathological confirmation, the clinical gold standard for endometriosis diagnosis. - The research was also published in the Journal of Minimally Invasive Gynecology, the official journal of the American Association of Gynecologic Laparoscopists, at the published study . The details: - HerResolve is a multi-omic blood test that measures three microRNAs, three protein biomarkers and one steroid hormone biomarker. - The assay uses qPCR and immunoassay technologies. - Patient age and body mass index are also fed into a proprietary AI-driven random forest machine-learning model. - The validation study included 298 women of reproductive age across multiple clinical sites. - Reported performance included an AUC of 0.944, 80% sensitivity and 97.5% specificity. - HerResolve identified 61.5% of true positive cases that were missed by transvaginal ultrasound and/or MRI. - HerAnova says HerResolve is the first and only commercially available non-invasive blood test developed to detect endometriosis, with access at select IVF and reproductive medicine centers in the U.S. - The company says HerResolve is intended to complement existing clinical pathways and help identify patients who may benefit from further diagnostic evaluation or empirical treatment. Between the lines: - The data position blood-based molecular testing as a possible complement to imaging, not a replacement for all existing workups. - The 61.5% figure suggests the assay may add value in patients whose disease is not visible on ultrasound or MRI. - The presentation also fits a broader push in women’s health to move diagnosis earlier and away from invasive procedures. - Farideh Bischoff, HerAnova’s chief medical officer, said the findings could help shorten diagnostic delays and enable earlier treatment interventions. - Penny Wan, HerAnova’s chairwoman, said delayed diagnosis carries consequences including worsening pain, declining fertility and higher healthcare burden. What’s next: - HerAnova says a prospective validation study is underway across geographically and ethnically diverse patient populations. - The company is also running longitudinal analyses to assess whether the assay can help monitor treatment response over time. - HerAnova is continuing engagement with the endocrinology community as it looks to broaden clinical utility and adoption. The bottom line: - HerAnova’s latest data suggest HerResolve could add meaningful diagnostic power for symptomatic women with suspected endometriosis, especially when imaging comes back negative.